
CLAIMS

1. A compound of the formula (I):



(I)

wherein

W, X and Y are each independently CH, C(R^4) or N;

Z is C(R^6);

R^1 and R^2 are each independently hydrogen or C_{1-6} alkyl; or R^1 and R^2 taken together with the carbon atom to which they are attached may form a 5- or 6-membered carbocycle or heterocycle, either of which is optionally substituted with 1, 2, 3, 4 or 5 R^a;

R^3 and R^4 are each independently halo or a group selected from C_{1-6} alkyl, C_{1-6} alkoxy, carbocyclyl and heterocyclyl, any of which is optionally substituted with 1, 2, 3, 4 or 5 R^a;

R^5 and R^6 taken together with the carbon atom to which they are attached may form a 5- or 6-membered heterocycle which is optionally substituted with 1, 2, 3, 4 or 5 R^a;

each R^a is independently selected from halogen, trifluoromethyl, cyano, oxo, nitro, -OR^b, -$C(O)R^b$, -$C(O)OR^b$, -$OC(O)R^b$, -$S(O)_lR^b$, -$N(R^b)R^c$, -$N(R^b)C(O)R^c$, -$C(O)N(R^b)R^c$, -$S(O)_lN(R^b)R^c$ and R^d;

R^b and R^c are each independently hydrogen or R^d;

R^d is selected from hydrocarbyl (e.g. C_{1-6}alkyl), carbocyclyl, carbocyclyl-C_{1-6}alkyl, and heterocyclyl, each of which is optionally substituted with 1, 2, 3, 4 or 5 substituents independently selected from halogen, cyano, amino, hydroxy, C_{1-6} alkyl, C_{1-6} alkoxy;

l is 0, 1 or 2; and

m and n are each independently 1, 2 or 3;

or a pharmaceutically acceptable salt or N-oxide thereof;

subject to the proviso that said compound is not one of the following:

8-(3-fluoropyridin-4-yl)-2-(trans-4-hydroxycyclohexyl)-2,8-diazaspiro[4.5]decan-1-one;


[2-(2,6-diethyl-phenyl)-4-(1,4-dioxa-8-aza-spiro[4.5]dec-8-yl)-6-methyl-pyrimidin-5-ylmethyl]-methyl-(1S)-(1,2,3,4-tetrahydro-naphthalen-1-yl)-amine;

(5R)-7-(3-fluoropyridin-4-yl)-2-(trans-4-hydroxycyclohexyl)-2,7-diazaspiro[4.5]decan-1-one;

or

7-(3-fluoropyridin-4-yl)-2-(4-hydroxy-1-adamantyl)-2,7-diazaspiro[4.5]decan-1-one.

2. A compound according to claim 1, which is of the formula (II):



(II)

wherein T is a bond or $-CH_2-$.

3. A compound according to claim 1 or claim 2, wherein X and Y are each CH.

4. A compound according to any preceding claim, wherein W is $C(R^4)$ or N.

5. A compound according to claim 4, wherein R^4 is halo.

6. A compound according to any preceding claim, wherein R^3 is halo or a group selected from C_{1-6} alkyl, aryl or heteroaryl, any of which is optionally substituted with 1, 2, 3, 4 or 5 R^a.


7. A compound according to claim 6, wherein R^3 is halo or a group selected from C_{1-6} alkyl, phenyl, pyrazolyl, triazolyl, oxazolyl, isoxazolyl, pyridinyl, pyridazinyl, pyrimidinyl and thiophenyl, any of which is optionally substituted with 1, 2, 3, 4 or 5 R^a.

8. A compound according to claim 1, wherein R^5 and R^6 taken together with the carbon atom to which they are attached form a heterocycle containing a ring amide group, wherein the heterocycle is optionally substituted with 1, 2, 3, 4 or 5 R^a.

9. A compound according to claim 8, wherein R^5 and R^6 taken together with the carbon atom to which they are attached form oxazolidone or 2-oxopyrrolidine, either of which is optionally substituted with 1, 2 or 3 R^a.

10. A compound which is selected from any one of the following:
8-(3,5-dichloropyridin-4-yl)-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one;
8-(3,5-dichloropyridin-4-yl)-2,8-diazaspiro[4.5]decan-1-one;
8-(3-chloro-5-phenylpyridin-4-yl)-2,8-diazaspiro[4.5]decan-1-one;
or a pharmaceutically acceptable salt or N-oxide thereof.

11. A compound according to any one of claims 1 to 10, or a compound of the formula (I):



(I)

wherein

W, X and Y are each independently CH, $C(R^4)$ or N;

Z is $C(R^6)$;

R^1 and R^2 are each independently hydrogen or C_{1-6} alkyl; or R^1 and R^2 taken together with the carbon atom to which they are attached may form a 5- or 6-membered carbocycle or heterocycle, either of which is optionally substituted with 1, 2, 3, 4 or 5 R^a;

R^3 and R^4 are each independently halo or a group selected from C_{1-6} alkyl, C_{1-6} alkoxy, carbocyclyl and heterocyclyl, any of which is optionally substituted with 1, 2, 3, 4 or 5 R^a;

R^5 and R^6 taken together with the carbon atom to which they are attached may form a 5- or 6-membered heterocycle which is optionally substituted with 1, 2, 3, 4 or 5 R^a;

each R^a is independently selected from halogen, trifluoromethyl, cyano, oxo, nitro, $-OR^b$, $-C(O)R^b$, $-C(O)OR^b$, $-OC(O)R^b$, $-S(O)_iR^b$, $-N(R^b)R^c$, $-N(R^b)C(O)R^c$,

$-C(O)N(R^b)R^c$, $-S(O)_iN(R^b)R^c$ and R^d;

R^b and R^c are each independently hydrogen or R^d;

R^d is selected from hydrocarbyl (e.g. C_{1-6}alkyl), carbocyclyl, carbocyclyl-C_{1-6}alkyl, and heterocyclyl, each of which is optionally substituted with 1, 2, 3, 4 or 5 substituents independently selected from halogen, cyano, amino, hydroxy, C_{1-6} alkyl, C_{1-6} alkoxy;

l is 0, 1 or 2; and

m and n are each independently 1, 2 or 3;

or a pharmaceutically acceptable salt or N-oxide thereof;
for use in the treatment and/or prophylaxis of cancer.

12. A compound according to claim 11, wherein the cancer is a cancer of the colon, breast or liver.


13. A compound of the formula (I) as defined in any one of claims 1 to 10, or a pharmaceutically acceptable salt or N-oxide thereof, with the proviso that R^4 is not an optionally substituted imidazolyl group.

14. A compound of claim 13, or a pharmaceutically acceptable salt or N-oxide thereof for therapeutic use.

15. A pharmaceutical formulation comprising a compound of claim 13 or a pharmaceutically acceptable salt or N-oxide thereof and a pharmaceutically acceptable carrier or excipient.

CLAIMS

1. A compound of the formula (I):



(I)

wherein

W, X and Y are each independently CH, C(R^4) or N;

Z is C(R^6);

R^1 and R^2 are each independently hydrogen or C_{1-6} alkyl; or R^1 and R^2 taken together with the carbon atom to which they are attached may form a 5- or 6-membered carbocycle or heterocycle, either of which is optionally substituted with 1, 2, 3, 4 or 5 R^a;

R^3 and R^4 are each independently halo or a group selected from C_{1-6} alkyl, C_{1-6} alkoxy, carbocyclyl and heterocyclyl, any of which is optionally substituted with 1, 2, 3, 4 or 5 R^a;

R^5 and R^6 taken together with the carbon atom to which they are attached form a 5- or 6-membered heterocycle which is optionally substituted with 1, 2, 3, 4 or 5 R^a;

each R^a is independently selected from halogen, trifluoromethyl, cyano, oxo, nitro, -OR^b, -$C(O)R^b$, -$C(O)OR^b$, -$OC(O)R^b$, -$S(O)_lR^b$, -$N(R^b)R^c$, -$N(R^b)C(O)R^c$, -$C(O)N(R^b)R^c$, -$S(O)_lN(R^b)R^c$ and R^d;

R^b and R^c are each independently hydrogen or R^d;

R^d is selected from hydrocarbyl, carbocyclyl, carbocyclyl-C_{1-6}alkyl, and heterocyclyl, each of which is optionally substituted with 1, 2, 3, 4 or 5 substituents independently selected from halogen, cyano, amino, hydroxy, C_{1-6} alkyl, C_{1-6} alkoxy;

l is 0, 1 or 2; and

m and n are each independently 1, 2 or 3;

or a pharmaceutically acceptable salt or N-oxide thereof;

subject to the proviso that said compound is not one of the following:

8-(3-fluoropyridin-4-yl)-2-(trans-4-hydroxycyclohexyl)-2,8-diazaspiro[4.5]decan-1-one;


[2-(2,6-diethyl-phenyl)-4-(1,4-dioxa-8-aza-spiro[4.5]dec-8-yl)-6-methyl-pyrimidin-5-ylmethyl]-methyl-(1S)-(1,2,3,4-tetrahydro-naphthalen-1-yl)-amine;

(5R)-7-(3-fluoropyridin-4-yl)-2-(trans-4-hydroxycyclohexyl)-2,7-diazaspiro[4.5]decan-1-one;

or

7-(3-fluoropyridin-4-yl)-2-(4-hydroxy-1-adamantyl)-2,7-diazaspiro[4.5]decan-1-one.

2. A compound according to claim 1, which is of the formula (II):



(II)

wherein T is a bond or $-CH_2-$.

3. A compound according to claim 1 or claim 2, wherein X and Y are each CH.

4. A compound according to any preceding claim, wherein W is $C(R^4)$ or N.

5. A compound according to claim 4, wherein R^4 is halo.

6. A compound according to any preceding claim, wherein R^3 is halo or a group selected from C_{1-6} alkyl, aryl or heteroaryl, any of which is optionally substituted with 1, 2, 3, 4 or 5 R^a.


7. A compound according to claim 6, wherein R^3 is halo or a group selected from C_{1-6} alkyl, phenyl, pyrazolyl, triazolyl, oxazolyl, isoxazolyl, pyridinyl, pyridazinyl, pyrimidinyl and thiophenyl, any of which is optionally substituted with 1, 2, 3, 4 or 5 R^a.

8. A compound according to claim 1, wherein R^5 and R^6 taken together with the carbon atom to which they are attached form a heterocycle containing a ring amide group, wherein the heterocycle is optionally substituted with 1, 2, 3, 4 or 5 R^a.

9. A compound according to claim 8, wherein R^5 and R^6 taken together with the carbon atom to which they are attached form oxazolidone or 2-oxopyrrolidine, either of which is optionally substituted with 1, 2 or 3 R^a.

10. A compound which is selected from any one of the following:
8-(3,5-dichloropyridin-4-yl)-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one;
8-(3,5-dichloropyridin-4-yl)-2,8-diazaspiro[4.5]decan-1-one;
8-(3-chloro-5-phenylpyridin-4-yl)-2,8-diazaspiro[4.5]decan-1-one;
or a pharmaceutically acceptable salt or N-oxide thereof.

11. Use of a compound according to any one of claims 1 to 10, or a compound of the formula (I):



(I)

wherein

W, X and Y are each independently CH, $C(R^4)$ or N;

Z is $C(R^6)$;

R^1 and R^2 are each independently hydrogen or C_{1-6} alkyl; or R^1 and R^2 taken together with the carbon atom to which they are attached may form a 5- or 6-membered carbocycle or heterocycle, either of which is optionally substituted with 1, 2, 3, 4 or 5 R^a;

R^3 and R^4 are each independently halo or a group selected from C_{1-6} alkyl, C_{1-6} alkoxy, carbocyclyl and heterocyclyl, any of which is optionally substituted with 1, 2, 3, 4 or 5 R^a;

R^5 and R^6 taken together with the carbon atom to which they are attached form a 5- or 6-membered heterocycle which is optionally substituted with 1, 2, 3, 4 or 5 R^a;

each R^a is independently selected from halogen, trifluoromethyl, cyano, oxo, nitro, $-OR^b$, $-C(O)R^b$, $-C(O)OR^b$, $-OC(O)R^b$, $-S(O)_iR^b$, $-N(R^b)R^c$, $-N(R^b)C(O)R^c$,

$-C(O)N(R^b)R^c$, $-S(O)_iN(R^b)R^c$ and R^d;

R^b and R^c are each independently hydrogen or R^d;

R^d is selected from hydrocarbyl (e.g. C_{1-6}alkyl), carbocyclyl, carbocyclyl-C_{1-6}alkyl, and heterocyclyl, each of which is optionally substituted with 1, 2, 3, 4 or 5 substituents independently selected from halogen, cyano, amino, hydroxy, C_{1-6} alkyl, C_{1-6} alkoxy;

l is 0, 1 or 2; and

m and n are each independently 1, 2 or 3;

or a pharmaceutically acceptable salt or N-oxide thereof;
for the manufacturing of a medicament for the treatment and/or prophylaxis of cancer.

12. The use according to claim 11, wherein the cancer is a cancer of the colon, breast or liver.

13. A compound of the formula (I) as defined in any one of claims 1 to 10, or a pharmaceutically acceptable salt or N-oxide thereof, with the proviso that R^4 is not an optionally substituted imidazolyl group.

14. A pharmaceutical formulation comprising a compound of claim 13 or a pharmaceutically acceptable salt or N-oxide thereof and a pharmaceutically acceptable carrier or excipient.